At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Double-blind Comparative Study of the Efficacy and Safety of E3810 10mg Once and Twice Daily in Maintenance Therapy for PPI Resistant Gastroesophageal Reflux Disease Patients
In Brief
A Phase 3 clinical trial evaluating Rabeprazole for Gastroesophageal Reflux Disease. Completed, enrolled 517 participants across 61 sites.
Detailed Summary
The purpose of this study is to assess the efficacy and safety of rabeprazole 10mg once and twice daily in maintenance therapy for PPI resistant gastroesophageal reflux disease patients.
Study Details
Timeline
Interventions
Rabeprazole 10 mg was administered orally twice daily during the treatment period for 8 weeks (unblinded).
Rabeprazole 20 mg was administered orally twice daily during the treatment period for 8 weeks (unblinded).
Rabeprazole 10 mg or 20 mg were administered orally twice daily during the treatment period (unblinded), and 10 mg was administered once daily during the maintenance period (double-blind).
Rabeprazole 10 or 20 mg were administered orally twice daily during the treatment period (unblinded), and 10 mg was administered twice daily during the maintenance period (double-blind).